Niaspan

Pellagra, Hardening of the Arteries, dietary supplementation + 14 more
Treatment
8 FDA approvals
20 Active Studies for Niaspan

What is Niaspan

NiacinThe Generic name of this drug
Treatment SummaryNiacin is a B vitamin used to replenish vitamin deficiencies and reduce the levels of fats in the bloodstream. It can also help reduce the risk of heart attacks.
O-Cal FA multivitaminis the brand name
image of different drug pills on a surface
Niaspan Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
O-Cal FA multivitamin
Niacin
1970
106

Approved as Treatment by the FDA

Niacin, also known as O-Cal FA multivitamin, is approved by the FDA for 8 uses which include High Cardiovascular Risk and Hyperlipidemia .
High Cardiovascular Risk
Used in combination with other therapies
Hyperlipidemia
Used in combination with Sevelamer to help manage Hyperlipidemias
Hardening of the Arteries
Used in combination with Sevelamer to help manage Atherosclerosis
High Cholesterol
Used in combination with Sevelamer to help manage Hyperlipidemias
Coronary Artery Disease
Used in combination with Sevelamer to help manage history of coronary artery disease
dietary supplementation
Used in combination with Niacin for dietary supplementation
Primary Hypercholesterolemia
Used in combination with other therapies
Dietary Modifications
Used in combination with other therapies

Effectiveness

How Niaspan Affects PatientsNiacin is a B vitamin used to treat vitamin deficiencies and certain types of high cholesterol. It helps to lower the bad types of cholesterol (very low density lipoproteins and low density lipoproteins) and increase the good type (high density lipoproteins). Usually 500-2000mg is taken orally each day, but some people (those with diabetes, kidney problems, hypothyroidism, or elderly people taking niacin with simvastatin or lovastatin) are at risk of muscle problems like myopathy and rhabdomyolysis.
How Niaspan works in the bodyNiacin helps reduce your levels of lipids and proteins that contain lipids, like apolipoprotein B (apo B). It does this by restricting the production of triglycerides in the liver, which also reduces apo B levels. Niacin also stops the breakdown of a type of protein called high density lipoprotein (HDL), which leads to higher levels and longer life of HDL.

When to interrupt dosage

The prescribed amount of Niaspan is reliant upon the diagnosed condition, for example inadequate response to diet, Dietary Modifications and Pellagra. The degree of dosage changes depending on the method of delivery (e.g. Oral or Tablet - Oral) detailed in the table beneath.
Condition
Dosage
Administration
Combined Modality Therapy
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Lozenge, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Capsule, extended release, Capsule, extended release - Oral, Powder - Oral, Powder, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable, Tablet, chewable - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Kit - Oral, Solution, Lozenge - Oral, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated
Dietary Modifications
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Lozenge, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Capsule, extended release, Capsule, extended release - Oral, Powder - Oral, Powder, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable, Tablet, chewable - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Kit - Oral, Solution, Lozenge - Oral, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated
Coronary Artery Disease
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Lozenge, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Capsule, extended release, Capsule, extended release - Oral, Powder - Oral, Powder, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable, Tablet, chewable - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Kit - Oral, Solution, Lozenge - Oral, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated
Risk of pancreatitis
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Lozenge, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Capsule, extended release, Capsule, extended release - Oral, Powder - Oral, Powder, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable, Tablet, chewable - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Kit - Oral, Solution, Lozenge - Oral, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated
inadequate response to diet
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Lozenge, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Capsule, extended release, Capsule, extended release - Oral, Powder - Oral, Powder, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable, Tablet, chewable - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Kit - Oral, Solution, Lozenge - Oral, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated
Hypertriglyceridemia
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Lozenge, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Capsule, extended release, Capsule, extended release - Oral, Powder - Oral, Powder, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable, Tablet, chewable - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Kit - Oral, Solution, Lozenge - Oral, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated
High Cholesterol
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Lozenge, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Capsule, extended release, Capsule, extended release - Oral, Powder - Oral, Powder, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable, Tablet, chewable - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Kit - Oral, Solution, Lozenge - Oral, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated
Hardening of the Arteries
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Lozenge, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Capsule, extended release, Capsule, extended release - Oral, Powder - Oral, Powder, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable, Tablet, chewable - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Kit - Oral, Solution, Lozenge - Oral, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated
dietary supplementation
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Lozenge, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Capsule, extended release, Capsule, extended release - Oral, Powder - Oral, Powder, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable, Tablet, chewable - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Kit - Oral, Solution, Lozenge - Oral, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated
Primary Hypercholesterolemia
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Lozenge, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Capsule, extended release, Capsule, extended release - Oral, Powder - Oral, Powder, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable, Tablet, chewable - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Kit - Oral, Solution, Lozenge - Oral, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated
cholesterol
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Lozenge, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Capsule, extended release, Capsule, extended release - Oral, Powder - Oral, Powder, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable, Tablet, chewable - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Kit - Oral, Solution, Lozenge - Oral, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated
Myocardial Infarction
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Lozenge, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Capsule, extended release, Capsule, extended release - Oral, Powder - Oral, Powder, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable, Tablet, chewable - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Kit - Oral, Solution, Lozenge - Oral, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated
Hyperlipidemias
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Lozenge, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Capsule, extended release, Capsule, extended release - Oral, Powder - Oral, Powder, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable, Tablet, chewable - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Kit - Oral, Solution, Lozenge - Oral, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated
Triglycerides
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Lozenge, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Capsule, extended release, Capsule, extended release - Oral, Powder - Oral, Powder, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable, Tablet, chewable - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Kit - Oral, Solution, Lozenge - Oral, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated
Dyslipidemias
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Lozenge, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Capsule, extended release, Capsule, extended release - Oral, Powder - Oral, Powder, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable, Tablet, chewable - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Kit - Oral, Solution, Lozenge - Oral, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated
Pellagra
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Lozenge, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Capsule, extended release, Capsule, extended release - Oral, Powder - Oral, Powder, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable, Tablet, chewable - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Kit - Oral, Solution, Lozenge - Oral, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated
High Cardiovascular Risk
, 500.0 mg, 750.0 mg, 1000.0 mg, 15.0 mg, 12.2 mg/mL, 10.0 mg, 0.02 mg/mL, 3.0 mg, 20.0 mg, 6.0 mg, 100.0 mg, 475.0 mg, 50.0 mg, 300.0 mg, 400.0 mg, 30.0 mg, 250.0 mg, 12.5 mg, 8.3 mg, 6.6 mg, 11.5 mg, 13.5 mg, 25.0 mg, 8.0 mg/mL, 0.2 mg, 125.0 mg, 375.0 mg, 0.15 mg, 5.0 mg, 2.5 mg, 17.0 mg, 0.5 mg, 1.8 mg, 1.5 mg, 18.0 mg, 200.0 mg, 0.33 mg, 19.0 mg, 75.0 mg, 0.55 mg, 60.0 mg, 17.5 mg, 3.34 mg, 22.5 mg, 6.25 mg, 1.0 mg, 1.66 mg, 7.0 mg, 3.75 mg, 8.0 mg, 12.0 mg, 16.7 mg, 6.67 mg, 7.5 mg, 35.0 mg, 45.0 mg, 40.0 mg, 3.3 mg, 52.0 mg, 2.0 mg, 0.018 mg/mg, 0.13 mg/mL, 15.0 mg/mL, 18.0 mg/mL, 0.2 mg/mL, 10.0 mg/mL, 0.002 mg/mg, 14.5 mg/mL, 30.0 mg/mL, 100.0 mg/mL, 800.0 mg/mL
, Tablet, film coated, extended release, Oral, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Liquid - Oral, Liquid, Topical, Shampoo, Shampoo - Topical, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled, Capsule, liquid filled - Oral, Lozenge, Intramuscular; Intravenous, Solution - Intramuscular; Intravenous, Capsule, extended release, Capsule, extended release - Oral, Powder - Oral, Powder, Tablet, extended release; Tablet, multilayer, extended release, Tablet, extended release; Tablet, multilayer, extended release - Oral, Solution / drops, Tablet, chewable, Tablet, chewable - Oral, Tablet, Delayed Release - Oral, Solution - Oral, Tablet, Delayed Release, Capsule, gelatin coated - Oral, Kit - Oral, Solution, Lozenge - Oral, Solution / drops - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Capsule, gelatin coated, Kit, Tablet, coated - Oral, Tablet, coated, Tablet, film coated - Oral, Tablet, film coated

Warnings

Niaspan Contraindications
Condition
Risk Level
Notes
Hypervitaminosis
Do Not Combine
Liver Dysfunction
Do Not Combine
Transaminases
Do Not Combine
Hemorrhage
Do Not Combine
Liver Diseases
Do Not Combine
Peptic Ulcer
Do Not Combine
Transaminases
Do Not Combine
There are 20 known major drug interactions with Niaspan.
Common Niaspan Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Niacin.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Niacin.
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Niacin.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Niacin.
Alpelisib
Major
The metabolism of Alpelisib can be decreased when combined with Niacin.
Niaspan Toxicity & Overdose RiskAn overdose of niacin can cause prolonged low blood pressure. If this occurs, supportive treatments such as giving fluids intravenously may be necessary. In mice, the toxic dose of niacin is 3720mg/kg, in rabbits it is 4550mg/kg, in rats it is 7000mg/kg, and in rats the toxic dose when applied to the skin is higher than 2000mg/kg.
image of a doctor in a lab doing drug, clinical research

Niaspan Novel Uses: Which Conditions Have a Clinical Trial Featuring Niaspan?

At present, 44 active trials are underway to assess the potential of Niaspan to address inadequate dietary responses, Cholesterol elevation and Type II Hyperlipidaemia.
Condition
Clinical Trials
Trial Phases
Coronary Artery Disease
0 Actively Recruiting
dietary supplementation
0 Actively Recruiting
High Cholesterol
17 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Early Phase 1
Dyslipidemias
1 Actively Recruiting
Phase 2
Pellagra
0 Actively Recruiting
cholesterol
4 Actively Recruiting
Phase 3, Not Applicable
Hyperlipidemias
0 Actively Recruiting
Risk of pancreatitis
0 Actively Recruiting
Hardening of the Arteries
18 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Phase 3
Primary Hypercholesterolemia
8 Actively Recruiting
Phase 3, Phase 2, Not Applicable
Combined Modality Therapy
0 Actively Recruiting
High Cardiovascular Risk
2 Actively Recruiting
Phase 2, Phase 3
Dietary Modifications
3 Actively Recruiting
Early Phase 1, Not Applicable, Phase 2
Triglycerides
0 Actively Recruiting
Hypertriglyceridemia
5 Actively Recruiting
Phase 3
Myocardial Infarction
0 Actively Recruiting
inadequate response to diet
0 Actively Recruiting

Niaspan Reviews: What are patients saying about Niaspan?

5Patient Review
6/26/2012
Niaspan for High Cholesterol
I was on this drug for about 4 months. Did nothing for my Cholesterol level. Never got over the burning from the inside out, extreme redness, and itching.
5Patient Review
8/12/2013
Niaspan for Combined High Blood Cholesterol and Triglyceride Level
I saw a significant reduction in cholesterol and triglyceride levels after just four months of using this medication, and my HDL level also increased. I'm very pleased with the results.
5Patient Review
1/27/2015
Niaspan for Combined High Blood Cholesterol and Triglyceride Level
Niaspan has been effectively keeping my levels in a good range for nine years now. Welchol was added two years ago and my cholesterol levels are now normal. Plus, my HDL is above 80 and T-Chol/HDL is below 3.5
5Patient Review
9/13/2014
Niaspan for Combined High Blood Cholesterol and Triglyceride Level
I have been taking this medication for a long time and have had great results. My blood work is always clean and my doctor is happy with the results. However, I am starting to become concerned with some of the recent studies that have come out.
4.7Patient Review
7/26/2012
Niaspan for Combined High Blood Cholesterol and Triglyceride Level
I have been on Niaspan for a few years now and I am beginning to wonder if it is causing more harm than good. I have noticed that injuries are more easily obtained and last longer, as well as different side effects such as burning in the sides of my heels, nausea, vomiting, upset stomach, and pain in the bottom of my feet. The numbers seem to be helpful, but I'm just concerned that it's ruining me in some way.
4.3Patient Review
7/27/2013
Niaspan for Combined High Blood Cholesterol and Triglyceride Level
I've experienced some strange things since starting to use Niaspan. My legs feel weak and painful, and I've been hiccupping for days now with no relief in sight. I'm going to stop taking the medication for a while and see if these symptoms go away. Statins are worse, so I didn't want to read about side effects until now in case I started experiencing them myself.
4.3Patient Review
8/8/2012
Niaspan for High Amount of Triglyceride in the Blood
I started taking Niaspan in April 2012. My total cholesterol was 270 and my bad cholesterol was 160. After eight weeks of taking the medication, along with oat bran, my total cholesterol was 202 and my bad cholesterol was 131. I highly recommend this book to anyone seeking similar results."
3.7Patient Review
11/9/2012
Niaspan for Combined High Blood Cholesterol and Triglyceride Level
I took this medication for six months at a dosage of 500mg per day, and then increased it to 1000mg. My cholesterol levels have lowered somewhat, but I've been dealing with really uncomfortable burning and tingling skin. Additionally, my blood sugar has risen above what is considered normal.
3.3Patient Review
6/6/2012
Niaspan for Combined High Blood Cholesterol and Triglyceride Level
3Patient Review
10/16/2012
Niaspan for High Cholesterol
I had been taking this medication for a few weeks with no issues until last night. I woke up to my insides burning and it lasted around half an hour. It was so severe that I'm seeing my doctor in the morning. Even though this drug has helped me a lot (my triglycerides dropped from 250 to 91), I don't know if I can continue taking it.
2.3Patient Review
4/1/2019
Niaspan for High Cholesterol
One possible side effect of this medicine is blotchy skin, which I unfortunately experienced. Now, I have what look like age spots on my legs.
1.7Patient Review
5/11/2013
Niaspan for High Cholesterol
I took the 500 mg dosage for 8 days as recommended. However, I started to feel really tired and achy; I attributed this to the statins I had just stopped taking. Then, as per my doctor's orders, I went up to 1000 mg. Immediately, I felt even more lethargic and out of it. Not to mention, my urine became discolored after only 5 days. So,I stopped taking it and gradually the aches and fatigue went away.
1.7Patient Review
9/14/2012
Niaspan for Low HDL Cholesterol
I found this medication to be effective; it did what it said it would do. I took 1000 MG from the beginning, only at night before bed. I didn't experience any flushing but occasionally felt a twisted feeling. I'm in a different country now and my new doctor says this drug is experimental, very expensive, and not stocked by hospitals. We will monitor my LDL and triglyceride levels; if necessary, I will reorder the medication.
1.3Patient Review
9/23/2013
Niaspan for Combined High Blood Cholesterol and Triglyceride Level
At first, I was on a lower dosage which didn't do much. So my doctor upped it to 1500mg... and then my liver enzymes and potassium levels went up. I was constantly throwing up and feeling very tired and lightheaded. My doctor took me off of the medication for 3 weeks to see how I would fare without it.
1Patient Review
5/16/2012
Niaspan for High Cholesterol
1Patient Review
6/1/2014
Niaspan for Combined High Blood Cholesterol and Triglyceride Level
I unfortunately had an allergic reaction to Niaspan 500mg where I developed hives.
1Patient Review
2/5/2013
Niaspan for High Cholesterol
Recently, my doctor upped my dosage to 2000 mg a day. Since then, I've been incredibly tired and have struggled to get enough sleep. Has anyone else experienced this problem?
1Patient Review
11/3/2016
Niaspan for Low HDL Cholesterol
I took Niaspan for one month and was okay. The second month, I started feeling a burning sensation on my legs which then spread to my arms. One night, it was so severe that I thought I might spontaneously combust. Thankfully, I stopped taking the drug immediately and saw a doctor who told me that I must be allergic to it.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about niaspan

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Niaspan a statin drug?

"Niaspan lowers triglycerides, but Mevacor is more effective for improving cholesterol levels. Statin side effects can be difficult to deal with, but the benefits might outweigh the risks."

Answered by AI

What is Niaspan 500mg used for?

"Niaspan is a medicine that you need a prescription for. It is used to lower the levels of bad cholesterol in your blood, and to increase the levels of good cholesterol. You can take it by itself, or with other medications."

Answered by AI

Is Niaspan the same as niacin?

"Niaspan is a medication that contains niacin, a type of B vitamin. Niaspan is used to lower cholesterol and triglycerides in the blood."

Answered by AI

What is the drug Niaspan used for?

"Niacin is a drug that helps to lower bad cholesterol and fats (LDL and triglycerides) in the blood and raise good cholesterol (HDL) when used in combination with a proper diet and exercise program. It is usually used after non-drug treatments have not been successful in lowering cholesterol levels."

Answered by AI

Clinical Trials for Niaspan

Image of The Worship Center Cristian Church in Birmingham, United States.

Black Impact for Heart Health

18+
Male
Birmingham, AL
The goal of this clinical trial is to evaluate the implementation and effectiveness of the Black Impact program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are: * Does participation in the Black Impact program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)? * What factors influence the adoption, delivery, and sustainability of the Black Impact program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcomes and program implementation factors. Participants will: * Attend a 90-minute weekly session for 24 weeks, including 45 minutes of physical activity led by a certified trainer and 45 minutes of health education delivered by trained coaches. * Receive one-on-one support from a community health worker to reduce barriers to care and engage with primary care. * Complete biometric health screenings and surveys at baseline, 12 weeks, and 24 weeks to assess clinical and behavioral outcomes. * Use a smartwatch, blood pressure cuff, and other tools to track progress in real time. * Participate in exit focus groups or interviews to share feedback about the intervention. * A subset of TWC leaders and interventionists (N=15) will also be interviewed to assess implementation, resource needs, and sustainability. This study uses the RE-AIM framework to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance, and aims to inform scalable strategies for improving CVH among Black men in trusted community settings.
Waitlist Available
Has No Placebo
The Worship Center Cristian Church
Have you considered Niaspan clinical trials? We made a collection of clinical trials featuring Niaspan, we think they might fit your search criteria.Go to Trials
Image of Sidney & Lois Eskenazi Hospital in Indianapolis, United States.

Composite Intervention for Metabolic Syndrome

18+
All Sexes
Indianapolis, IN
The objective of this study is to pilot a multifaceted, optimized intervention for metabolic syndrome (MetS) in emergency department patients to establish feasibility. Participants (n=20) will be randomized to intervention or control (usual care). The composite intervention will include an educational video outlining the adverse effects of MetS and the benefit of walking, a written exercise prescription with a defined goal of walking 150 minutes per week, a Fitbit accelerometer device, resources for healthy eating practices, periodic text message reminders, and an urgent referral to primary care and our health system's Healthy Me clinic for follow-up visit. Investigators hypothesize that this approach will change patient understanding and motivation to increase physical activity and healthy eating habits.
Recruiting
Has No Placebo
Sidney & Lois Eskenazi Hospital
Image of Duke University Medical Center in Durham, United States.

Cardiometabolic Prevention Clinic for Cardiovascular Disease

18+
All Sexes
Durham, NC
This project is studying whether a team-based specialty clinic can help people with type 2 diabetes and heart disease better manage their blood pressure and cholesterol. The clinic includes coordinated care from heart doctors, kidney doctors, diabetes specialists, and liver doctors. The study will compare two groups of patients: one receiving usual care from their primary care provider, and one referred to the Duke Cardiometabolic Prevention Clinic for multidisciplinary care. The main goals are to find out if this clinic improves blood pressure and cholesterol control over 12 months, increases use of recommended heart medications, and reduces hospital visits and other healthcare use. Participants will be randomly assigned to one of the two groups. Those referred to the clinic will: 1) Meet with a cardiologist for an initial evaluation. 2) Be referred to other specialists (such as endocrinology, nephrology, or hepatology) based on their needs. 3) Receive ongoing, coordinated care from a team of specialists working together to improve their heart and metabolic health.
Recruiting
Has No Placebo
Duke University Medical CenterNeha J Pagidipati, MD, MPH
Have you considered Niaspan clinical trials? We made a collection of clinical trials featuring Niaspan, we think they might fit your search criteria.Go to Trials
Image of Rush University Medical Center in Chicago, United States.

Health Coaching for Heart Disease

40 - 75
All Sexes
Chicago, IL
The goal of this longitudinal study is to investigate the role of virtual health coaching on mitigation of cardiometabolic disease risk in an underserved, food insecure population. The main questions it aims to answer are: * Does longitudinal, individualized health coaching directed at lifestyle modification reduce patient 10-year risk of heart attack or stroke? * Does longitudinal, individualized health coaching directed at lifestyle modification reduce rates of hypertension, hyperlipidemia, and diabetes? * Does longitudinal, individualized health coaching directed at lifestyle modification improve accessibility to healthcare? Researchers will investigate the effects of regularly scheduled health coaching sessions on composite cardiometabolic risk profile as well as individual modifiable cardiovascular risk factors. Participants will: * Participate in in-person cardiovascular screening, occuring at the time of enrollment, months 3 and 6. * Engage in virtual health coaching sessions to talk about diet, exercise, weight loss, blood pressure and diabetes control, and accessibility to healthcare * Keep a log of their blood pressure
Waitlist Available
Has No Placebo
Rush University Medical CenterDaniel Luger, MD
Image of (Benedict) UMass Memorial Medical Center - Adult Primary Care in Worcester, United States.

WE CARE SDOH System for Chronic Disease

Any Age
All Sexes
Worcester, MA
The goal of this clinical trial is to learn if the implementation of the WE CARE social determinants of health (SDOH) screening and referral intervention with an antiracist lens in primary care settings can lead to a meaningful decrease in chronic disease by monitoring conditions such as hypertension, diabetes, depression, hyperlipidemia, and asthma through clinical measures. The main question it aims to answer is: Does the WE CARE SDOH screening and referral intervention applying an antiracism lens informed implementation strategies have the potential to reduce racial/ethnic health inequities in chronic diseases for minoritized patients?
Recruiting
Has No Placebo
(Benedict) UMass Memorial Medical Center - Adult Primary Care (+2 Sites)
Image of Clinical Research Site 4 in Santa Clarita, United States.

Plozasiran for Hypertriglyceridemia

18+
All Sexes
Santa Clarita, CA
This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. Eligible participants will be randomly assigned in a double-blind manner to either receive plozasiran 25 mg by subcutaneous (SC) injection every three months (Q3M) or matching placebo. Enrolled participants will be counseled to remain on the specified low-fat diet and background medications throughout the study. Following completion of the double-blind treatment period, or if the participant has a positively adjudicated AP event (whichever occurs first), participants will transition to the 12-month Open-Label Extension (OLE) treatment period receiving plozasiran 25 mg by SC injection Q3M.
Phase 3
Recruiting
Clinical Research Site 4 (+9 Sites)Arrowhead Pharmaceuticals
Have you considered Niaspan clinical trials? We made a collection of clinical trials featuring Niaspan, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security